✦ LIBER ✦

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

✍ Scribed by Kang, Yoon-Koo; Muro, Kei; Ryu, Min-Hee; Yasui, Hirofumi; Nishina, Tomohiro; Ryoo, Baek-Yeol; Kamiya, Yukimasa; Akinaga, Shiro; Boku, Narikazu

Book ID: 121589136
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 234 KB
Volume: 32
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-0057-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

651 POSTER A Phase 1 dose escalation stu

651 POSTER A Phase 1 dose escalation study of ARQ 197, a selective inhibitor of the c-Met receptor in patients with metastatic solid tumors

✍ L. Rosen; A. Garcia; M. Mulay; C. Cunningham; J. Nemunaitis; N. Senzer; C. Li; A 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 50 KB

A phase II trial to evaluate gefitinib a

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

✍ A. Goncalves; M. Fabbro; C. Lhommé; L. Gladieff; J.-M. Extra; A. Floquet; L. Cha 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Second- and Third-generation Aromatase I

Second- and Third-generation Aromatase Inhibitors as First-line Endocrine Therapy in Postmenopausal Metastatic Breast Cancer Patients: A Pooled Analysis of the Randomised Trials

✍ Elledge, R.M. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 94 KB

‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as s

‘Tomudex’ (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II study

✍ A. Schulz; D. Garfield; W. Berry; D. Gordon; C. Lowery; M. Smith 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 116 KB

7105 Phase II trial of the oral multikin

7105 Phase II trial of the oral multikinase inhibitor BAY 73–4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC)

✍ Eisen, T.; Joensuu, H.; Nathan, P.; Harper, P.; Wojtukiewicz, M.; Nicholson, S.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

A phase II study of sabarubicin (MEN-107

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

✍ Francesco Caponigro; Pax Willemse; Roberto Sorio; Anne Floquet; Simon van Belle; 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 81 KB